In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Genocea Biosciences, Inc.. Trade Record

NASDAQ:GNCA Genocea Biosciences, Inc. stock gains 17.30% Exit Sep 14, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart GNCA Aug 24, 2017, priceSeries
About Genocea Biosciences, Inc.

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
97.67
Entry Date
Aug 24, 2017
Entry Price
34.16
Sell Date
Sep 14, 2017
Sell Price
40.07
Net Gain
17.30%
Hold Time
14 Trading Days